Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

12 Apr 2019

Abstract excerpt

PURPOSE: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)-derived lymphomas. We hypothesized that direct inhibition of EZH2 and histone deacetyltransferase (HDAC) would be synergistic in GC-derived lymphomas. EXPERIMENTAL DESIGN: findings. Pretreatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30979734
DOI: 10.1158/1078-0432.ccr-18-3989

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated LymphomasPMID 30979734Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.Semantic proximity Read ↗

Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.Semantic proximity Read ↗

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.Semantic proximity Read ↗

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesSemantic proximity Read ↗

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSemantic proximity Read ↗

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.Semantic proximity Read ↗

EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.